€81.10
-4.48%
Compare
Laboratorios vs Almirall S.ALaboratorios vs Faes Farma S.ALaboratorios vs Laboratorio ReigLaboratorios vs Labiana Health S.ALaboratorios vs Grifols, S.ALaboratorios vs IBEX 35 | MarketI

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Sep 2025

Income Metrics

Revenue 210.5M
Gross Profit 147.8M 70.23%
Operating Income 76.3M 36.25%
Net Income 58.0M 27.56%

Balance Sheet Metrics

Total Assets 922.1M
Total Liabilities 289.3M
Shareholders Equity 632.8M
Debt to Equity 0.46

Cash Flow Metrics

Operating Cash Flow 28.8M
Free Cash Flow 55.8M

Revenue & Profitability Trend

Quarter Income Flow i

Annual Income Flow i

Laboratorios Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 763.7M 829.5M 817.7M 648.7M 420.0M
Cost of Goods Sold i 285.4M 337.2M 298.1M 263.9M 178.7M
Gross Profit i 478.3M 492.3M 519.6M 384.8M 241.3M
Gross Margin % i 62.6% 59.3% 63.5% 59.3% 57.5%
Operating Expenses
Research & Development i - - - - -
Selling, General & Administrative i 39.4M 38.0M 32.8M 12.7M 11.4M
Other Operating Expenses i 95.7M 85.2M 100.2M 80.0M 59.3M
Total Operating Expenses i 135.1M 123.2M 133.0M 92.7M 70.7M
Operating Income i 179.5M 220.3M 255.8M 181.5M 77.4M
Operating Margin % i 23.5% 26.6% 31.3% 28.0% 18.4%
Non-Operating Items
Interest Income i 26.0K 7.0K 6.0K 68.0K 4.0K
Interest Expense i 2.0M 667.0K 606.0K 669.0K 806.0K
Other Non-Operating Income - - - - -
Pre-tax Income i 177.7M 220.4M 258.0M 182.6M 72.6M
Income Tax i 40.8M 50.1M 58.3M 29.6M 11.5M
Effective Tax Rate % i 23.0% 22.7% 22.6% 16.2% 15.9%
Net Income i 136.9M 170.3M 199.7M 153.1M 61.1M
Net Margin % i 17.9% 20.5% 24.4% 23.6% 14.5%
Key Metrics
EBITDA i 207.6M 245.6M 279.6M 202.7M 96.8M
EPS (Basic) i €2.68 €3.29 €3.73 €2.76 €1.10
EPS (Diluted) i €2.68 €3.29 €3.73 €2.76 €1.10
Basic Shares Outstanding i 51149498 51820146 53466000 55404000 55386000
Diluted Shares Outstanding i 51149498 51820146 53466000 55404000 55386000

Income Statement Trend

Laboratorios Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 27.2M 25.3M 124.9M 99.0M 53.2M
Short-term Investments i 227.0K - - - -
Accounts Receivable i 129.5M 143.3M 180.0M 150.2M 76.4M
Inventory i 330.0M 338.0M 311.9M 245.5M 227.2M
Other Current Assets 2.7M - - - -
Total Current Assets i 489.6M 509.3M 623.1M 506.4M 364.6M
Non-Current Assets
Property, Plant & Equipment i 116.6M 120.1M 97.3M 84.1M 77.0M
Goodwill i 34.0M 33.9M 35.7M 38.6M 41.4M
Intangible Assets i 34.0M 33.9M 35.7M 38.6M 41.4M
Long-term Investments - - - - -
Other Non-Current Assets 65.0K - - - -
Total Non-Current Assets i 342.4M 290.6M 255.6M 226.3M 209.9M
Total Assets i 832.0M 799.9M 878.7M 732.7M 574.4M
Liabilities
Current Liabilities
Accounts Payable i 86.9M 107.6M 123.9M 97.4M 63.5M
Short-term Debt i 23.7M 13.2M 12.7M 6.4M 5.1M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 5.2M - - - -
Total Current Liabilities i 156.7M 199.8M 293.9M 190.4M 122.9M
Non-Current Liabilities
Long-term Debt i 90.7M 52.2M 59.4M 66.7M 68.4M
Deferred Tax Liabilities i 366.0K 1.5M 677.0K 776.0K 929.0K
Other Non-Current Liabilities 2.7M - - - -
Total Non-Current Liabilities i 93.8M 56.5M 63.4M 71.3M 77.8M
Total Liabilities i 250.5M 256.4M 357.3M 261.7M 200.7M
Equity
Common Stock i 3.1M 3.2M 3.2M 3.4M 3.4M
Retained Earnings i 486.2M 555.5M 456.0M 445.4M 302.2M
Treasury Stock i 5.5M 107.7M 27.6M 66.1M 20.2M
Other Equity - - - - -
Total Shareholders Equity i 581.5M 543.5M 521.4M 471.0M 373.7M
Key Metrics
Total Debt i 114.4M 65.4M 72.1M 73.1M 73.5M
Working Capital i 333.0M 309.5M 329.2M 316.0M 241.7M

Balance Sheet Composition

Laboratorios Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i 177.7M 220.4M 258.0M 182.6M 72.6M
Depreciation & Amortization i - - - - -
Stock-Based Compensation i - - 0 1.4M 0
Working Capital Changes i 25.3M -10.5M -98.6M -99.4M -62.9M
Operating Cash Flow i 203.9M 208.2M 155.5M 79.0M 8.6M
Investing Activities
Capital Expenditures i -59.1M -53.4M -50.6M -40.2M -39.3M
Acquisitions i -19.1M 1.2M 0 - -
Investment Purchases i - 0 -5.9M 0 -
Investment Sales i 80.0K 88.0K 20.0K 0 -
Investing Cash Flow i -78.1M -52.1M -56.5M -40.2M -39.3M
Financing Activities
Share Repurchases i -89.7M -133.9M -177.0M -78.8M -37.3M
Dividends Paid i -56.5M -69.0M -51.0M -21.1M -9.7M
Debt Issuance i 97.0M 734.0K 1.4M 1.3M 1.4M
Debt Repayment i -51.7M -13.7M -6.8M -6.2M -13.2M
Financing Cash Flow i -53.6M -160.5M -154.2M -62.4M -21.2M
Free Cash Flow i 76.1M 58.1M 186.2M 108.5M 7.2M
Net Change in Cash i 72.2M -4.4M -55.2M -23.6M -51.9M

Cash Flow Trend

Laboratorios Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 36.12
Forward P/E 19.85
Price to Book 6.59
Price to Sales 5.89
PEG Ratio 19.85

Profitability Ratios

Profit Margin 18.89%
Operating Margin 25.15%
Return on Equity 22.33%
Return on Assets 12.11%

Financial Health

Current Ratio 3.13
Debt to Equity 18.04
Beta 0.33

Per Share Data

EPS (TTM) €2.37
Book Value per Share €12.99
Revenue per Share €14.54

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
ROVI 4.3B 36.12 6.59 22.33% 18.89% 18.04
Almirall S.A 2.8B 58.64 1.86 3.10% 4.14% 23.30
Faes Farma S.A 1.5B 19.60 2.05 10.82% 12.70% 58.11
Laboratorio Reig 220.6M 45.17 1.01 2.30% 1.49% 42.21
Labiana Health S.A 49.2M 42.50 7.81 23.11% 1.26% 998.21
Grifols, S.A 6.1B 15.58 1.19 6.17% 5.34% 126.83
Nippun Rana

Nippun Rana

Chasing the market trend!

Hi, I’m Nippun, a tech enthusiast from Haryana, India. I have been coding since 2010 and using my coding skills in the share market since 2020. I have been coding scripts in Pinescript that work on Tradingview app/web. I love learning about new technology and applying it to solve real-world problems. Coding and share-market are my passions, and I enjoy finding and fixing bugs in code. I aim to share my skill set and experience that can positively impact society. Feel free to connect with me, an...

Financial data is updated regularly. All figures are in the company's reporting currency.